HUE045337T2 - Eljárás primer hiperaldoszteronizmus diagnosztizálására - Google Patents

Eljárás primer hiperaldoszteronizmus diagnosztizálására

Info

Publication number
HUE045337T2
HUE045337T2 HUE14789218A HUE14789218A HUE045337T2 HU E045337 T2 HUE045337 T2 HU E045337T2 HU E14789218 A HUE14789218 A HU E14789218A HU E14789218 A HUE14789218 A HU E14789218A HU E045337 T2 HUE045337 T2 HU E045337T2
Authority
HU
Hungary
Prior art keywords
diagnosis
primary hyperaldosteronism
hyperaldosteronism
primary
Prior art date
Application number
HUE14789218A
Other languages
English (en)
Inventor
Marko Poglitsch
Cornelia Schwager
Oyen Dunja Van
Martin Leitner
Original Assignee
Attoquant Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20130189386 external-priority patent/EP2863228A1/en
Application filed by Attoquant Diagnostics Gmbh filed Critical Attoquant Diagnostics Gmbh
Publication of HUE045337T2 publication Critical patent/HUE045337T2/hu

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743Steroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483Physical analysis of biological material
    • G01N33/487Physical analysis of biological material of liquid biological material
    • G01N33/49Blood
    • G01N33/492Determining multiple analytes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2410/00Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids
    • G01N2410/02Angiotensins; Related peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Ecology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HUE14789218A 2013-10-18 2014-10-17 Eljárás primer hiperaldoszteronizmus diagnosztizálására HUE045337T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20130189386 EP2863228A1 (en) 2013-10-18 2013-10-18 Method for diagnosis of primary hyperaldosteronism
EP14152763 2014-01-28

Publications (1)

Publication Number Publication Date
HUE045337T2 true HUE045337T2 (hu) 2019-12-30

Family

ID=51794861

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14789218A HUE045337T2 (hu) 2013-10-18 2014-10-17 Eljárás primer hiperaldoszteronizmus diagnosztizálására

Country Status (13)

Country Link
US (2) US9829496B2 (hu)
EP (1) EP3058374B1 (hu)
JP (1) JP6397907B2 (hu)
CN (1) CN105683760A (hu)
AU (1) AU2014336122B2 (hu)
BR (1) BR112016007960B8 (hu)
CA (1) CA2926382C (hu)
DK (1) DK3058374T3 (hu)
EA (1) EA035289B1 (hu)
ES (1) ES2745099T3 (hu)
HU (1) HUE045337T2 (hu)
PL (1) PL3058374T3 (hu)
WO (1) WO2015055825A1 (hu)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10559377B2 (en) 2013-01-09 2020-02-11 Biomed Concepts Inc. Graphical user interface for identifying diagnostic and therapeutic options for medical conditions using electronic health records
EA035289B1 (ru) * 2013-10-18 2020-05-25 Аттоквант Диагностикс Гмбх Способ диагностики первичного гиперальдостеронизма
WO2017127459A1 (en) * 2016-01-19 2017-07-27 Biomed Concepts Inc. Method and system for identifying diagnostic and therapeutic options for medical conditions using electronic health records
CA3041724C (en) * 2016-11-17 2022-05-31 Laboratory Corporation Of America Holdings Methods and systems for measuring plasma renin activity
CN106770824A (zh) * 2016-12-21 2017-05-31 河南出入境检验检疫局检验检疫技术中心 利用高分辨质谱仪检测血浆中痕量醛固酮的方法
JP7067758B2 (ja) * 2017-06-30 2022-05-16 国立大学法人 新潟大学 試料中のアンジオテンシンペプチドの量を測定するための方法及びアンジオテンシンペプチドの定量キット
CN112037931B (zh) * 2020-07-15 2023-10-20 新疆维吾尔自治区人民医院 在疑似原发性醛固酮增多症中应用的醛固酮增多预测体系
CN112014509A (zh) * 2020-09-03 2020-12-01 复旦大学附属中山医院 同步测定样品中血管紧张素i和醛固酮的方法
CN113533552B (zh) * 2021-06-02 2023-08-29 杭州凯莱谱精准医疗检测技术有限公司 液相色谱串联质谱检测肾素活性过程中对影响arr药物同步检测的方法
CN117554603B (zh) * 2023-11-28 2024-05-10 中国医学科学院阜外医院 一种用于原发性醛固酮增多症初筛的标志物组合及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919407A (en) * 1973-11-28 1975-11-11 De Castro Aurora L Fernandez Method for quantitative determination of renin activity in blood
JPH022935A (ja) * 1988-06-20 1990-01-08 Tosoh Corp アンジオテンシンの測定法
US5314804A (en) * 1992-03-24 1994-05-24 Serim Research Corporation Test for Helicobacter pylori
AU2002304965A1 (en) * 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
WO2007109733A2 (en) * 2006-03-21 2007-09-27 The Johns Hopkins University Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
EP2021324B1 (en) 2006-05-29 2011-12-14 NicOx S.A. Nitrated heterocyclic compounds as endothelin receptor antagonist
EP2129382A4 (en) 2007-02-21 2011-01-19 Univ Michigan COMPOSITIONS AND METHODS FOR TRANQUILIZATION OF THE CARDIAC MUSCLE
EP2225559B8 (en) * 2007-12-28 2016-12-21 F. Hoffmann-La Roche AG Assessment of physiological conditions
CN102586223A (zh) 2012-03-08 2012-07-18 南京大学 一种基于mypt1基因敲除建立新型高血压小鼠模型的方法及其用途
WO2013134472A1 (en) * 2012-03-08 2013-09-12 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation methods and systems for treatment of hyperaldosteronism
EA035289B1 (ru) * 2013-10-18 2020-05-25 Аттоквант Диагностикс Гмбх Способ диагностики первичного гиперальдостеронизма

Also Published As

Publication number Publication date
AU2014336122B2 (en) 2020-06-25
BR112016007960B1 (pt) 2023-03-07
EP3058374A1 (en) 2016-08-24
WO2015055825A1 (en) 2015-04-23
NZ717888A (en) 2022-03-25
US10295552B2 (en) 2019-05-21
US9829496B2 (en) 2017-11-28
EA201690796A1 (ru) 2016-08-31
AU2014336122A1 (en) 2016-04-07
US20180164330A1 (en) 2018-06-14
BR112016007960A8 (pt) 2020-03-17
EA035289B1 (ru) 2020-05-25
CN105683760A (zh) 2016-06-15
JP6397907B2 (ja) 2018-09-26
JP2017500538A (ja) 2017-01-05
ES2745099T3 (es) 2020-02-27
PL3058374T3 (pl) 2020-02-28
CA2926382C (en) 2020-06-02
US20160266151A1 (en) 2016-09-15
CA2926382A1 (en) 2015-04-23
BR112016007960B8 (pt) 2023-11-14
EP3058374B1 (en) 2019-06-26
DK3058374T3 (da) 2019-08-26

Similar Documents

Publication Publication Date Title
HRP20190600T1 (hr) Postupak za neinvazivnu procjenu genetičkih varijacija
HK1220765A1 (zh) 對樣本成像的方法
SG11201510747RA (en) Method for increasing expression of rna-encoded proteins
GB201401248D0 (en) Method of manufacture
HUE045337T2 (hu) Eljárás primer hiperaldoszteronizmus diagnosztizálására
HK1218014A1 (zh) 用以間接判定參考間距的方法
GB201412190D0 (en) Method of optimization for an application
HK1214240A1 (zh) 用於製備酰亞胺基二硫酰化合物的方法
PL3071969T3 (pl) Sposób analizy
GB201319875D0 (en) Method of measuring isotape ratio
GB201305231D0 (en) Method of Manufacture
IL241096A0 (en) Treatment methods
HK1220969A1 (zh) 用於合成伊立替康的方法
PL3071958T3 (pl) Sposób oceny potrzeb konserwacyjnych
GB201307256D0 (en) Diagnostic method
HK1216419A1 (zh) 合成方法
GB201509658D0 (en) Method of diagnosis
GB201221046D0 (en) Method of diagnosis
GB201400510D0 (en) Method of providing broadband connection
GB201311291D0 (en) Method of manufacture
GB201300370D0 (en) Method of calibrating asynchronies
GB201301262D0 (en) Method of manufacture
SG10201701021XA (en) Method of synthesis
GB201322778D0 (en) Method of treatment
GB201314882D0 (en) Method of treatment